Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer
ChiCTR2100052288Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of sintilimab in rectal adenocarcinoma (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Pathologic complete response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100052288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052288.